Generate:Biomedicines
@generate_biomed
As pioneers in generative biology, we're revolutionizing the way biotherapeutics are discovered and developed.
On Thursday, June 19, at 12:30pm, our CEO, @mike_nally, will join the final panel of #BIO2025: “Going It Alone…or Together?” The panel will explore how nationalism, policy shifts, and economic fragmentation are reshaping global biotech—raising questions about collaboration,…
Breakthroughs in biomanufacturing, biochemical modeling, and AI-enabled drug discovery are reshaping the biotech landscape. But they require more than vision—they demand infrastructure, coordination, and technical depth. On June 18, our co-founder and CTO, @ggrigoryanv, will…
Our Andover site is home to one of the largest private CryoEM labs in the country—a place where precision, data, and structural insights fuel progress every day. Recently, they focused on a different kind of precision: bowling. Pins were dropped, scores were settled, and the…
Today, we celebrate the birthday of Rosalind Franklin – the pioneering British chemist whose groundbreaking X-ray crystallography work at King’s College was instrumental in the discovery of DNA’s double-helix structure. Her contributions laid the foundation for structural biology…
What will determine which AI biotechs lead the next era of drug development? In her article for @PharmaScrip, @ScripMandy argues it won’t be model sophistication alone—but whether those models are used to solve the right problems. She points to @generate_biomed as a standout: a…
During our summer shutdown, members of #TeamGenerate traded their laptop screens and lab coats for two wheels – taking the road less traveled. From the rugged routes of the Lutsen 99er race in Minnesota’s Sawtooth Mountains to the winding, lavender-lined streets in Provence,…
ICYMI: What happens when #AI isn’t just layered onto biology—but built into it? In this conversation with Pierre Ferragu of New Street Research, our CEO, @mike_nally, shares how #TeamGenerate is using generative AI to intentionally design proteins and program biology—moving…
For #TeamGenerate, rest is a system feature—built in with the same intention as any part of our platform. Because sustainable progress takes clarity, and because innovation requires space to think, reset, and return with focus. Next week, we pause for our summer shutdown: a…
In her coverage of #BIO2025 (@IAmBiotech), @ScripMandy of @Citeline highlights how regulatory uncertainty and market constraints continue to weigh on biotech dealmaking and investment decisions across the industry. Our CEO, @mike_nally, shared our perspective on managing these…
Making an impact is in our DNA—whether it's reimagining what medicines can do or supporting the communities we call home. Recently, #TeamGenerate hosted a fundraiser for @HHCTweets to support early education, play spaces, and family services for children experiencing…
#TeamGenerate thrives on diverse thinking—and today, on International Women in Engineering Day, we honor the incredible contributions of the women engineers whose curiosity, creativity, and expertise power our platform. This year’s theme, #TogetherWeEngineer, reminds us that…
What does #PrideMonth look like at a company built for breakthroughs? From our annual tie-dye tradition to a company-wide social hour, #TeamGenerate is coming together this month to celebrate Pride—honoring identity, building connection, and strengthening the culture we are…
Oncology needs more than new medicines. It needs better ones—designed with intention, built to perform, and developed with the patient in mind. On June 17, our EVP, R&D, Alexandra Snyder, MD, will speak at @NYASciences' "12th Annual Frontiers in Cancer Immunotherapy Symposium”…
From commuting to community, we’re lucky to have a thriving network of cyclists —from casual riders to serious road warriors. Last week, members of our Bike Committee celebrated the end of #NationalBikeMonth with a group ride from our @BoyntonYardsMa HQ in Somerville to…
AI-driven biopharma deals show no sign of slowing, yet as Andrew Marshall notes in Biopharma Dealmakers (@Nature), few AI-designed molecules have achieved clinical validation. He highlights @generate_biomed as a "frontrunner," citing our collaboration with @Novartis as evidence…
Pharma isn’t just adopting AI. It’s being redefined by it. Today, our CEO, @mike_nally, joins Pierre Ferragu of New Street Research to open their new speaker series, "AI Transforming Industries". The conversation will explore the infrastructure behind this shift, the programs…
What happens when an AI-native company builds a drug development engine for the real world? On the FYI Podcast from @ARKInvest, hosts @wintonARK and @NMDespotARK talk with our CEO @mike_nally and CFO Jason Silvers about a system built to optimize not just timelines—but…
#TeamGenerate’s Mindset Awards recognize the behaviors that power our science. This time, we’re celebrating the winners of our #AudaciouslyAmbitious Award—honoring bold thinking, disciplined execution, and the drive to go beyond what’s expected. Alex Ayoub, Anil Bhate, Atreyi…
On the latest #CellAndGenePodcast, our EVP, R&D, Alex Snyder, MD, joins Erin Harris to talk about how we apply generative AI with intention. Alex discusses GB-0895—our TSLP-targeting antibody for asthma designed to extend half-life, improve potency, and reduce dosing frequency.…